The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has announced it is assessing new data on the potential risk of neurodevelopmental disorders (NDDs) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback